1. Shorr AF, Tabak YP, Killian AD et al. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006; 34: 2588–95.
2. UK Health Protection Agency. Voluntary reporting of Staphylococcus aureus bacteraemia in England, Wales, and Northern Ireland January–December 2008. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560519595 (accessed Nov 30, 2010)
3. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997–2003: cohort study. BMJ 2006; 333: 281.
4. Грувер К.П., Белобородов В.Б. Клиническое значение бактериемии у больных сепсисом. Клиническая микробиология и антибактериальная химиотерапия. 2011; 13 (1): 90–7.
5. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infec Dis 2011; 52: 1–38
6. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394–434.
7. Elliott TS, Foweraker J, Gould FK et al. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971–81.
8. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589–608.
9. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1–45.
10. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30: 2369–413.
11. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 2009; 48 (Suppl. 4): S260.
12. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14: 75–82.
13. Siegman-Igra Y, Reich P, Orni-Wasserlauf R et al. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 2005; 37: 572–8.
14. Khatib R, Johnson LB, Fakih MG et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38: 7–14.
15. Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 25–32. 
16. Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066–72.
17. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333–9.
18. Johnson LB, Almoujahed MO, Ilg K et al. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782–9.
19. Wilson R, Hamburger M. Fifteen years’ experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med 1957; 22: 437–57.
20. Fowler VG Jr, Sanders LL, Sexton DJ et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27: 478–86.
21. Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A et al. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore) 2009; 88: 1–22.
22. Murray RJ. Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern Med J 2005; 35 (Suppl. 2): S25–44.
23. Bradbury T, Fehring TK, Taunton M et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty 2009; 24 (Suppl. 6): 101–4.
24. Davis JS. Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 2005; 35 (Suppl. 2): S79–96.
25. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000; 31: 1170–4.

В.Б.Белобородов

ГБОУ ДПО РМАПО Минздрава России, Москва